With successful generation of humanized mice bearing individual patients’ immune systems, we expanded these efforts to prospective collection of BM-derived CD34+ cells from patients under active treatment along with tumor tissue from the same patient (ie, an autologous platform). Here, CD34 is linked to neoplasm.